Molecular Partners AG announced the dosing of first patients in the TACTIC Phase 2 proof-of-concept study of MP0317 in combination with chemoimmunotherapy for advanced biliary tract carcinoma. The randomized, multicenter study aims to recruit 75 patients with a 2-to-1 design and expects a data update in 2027 with trial completion in 2026. Molecular Partners AG is a clinical-stage biotech company developing DARPin therapeutics for cancer patients.